Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.5 Billion EUR | 215.71% |
| 2022 | 1.11 Billion EUR | 90.01% |
| 2021 | 585.07 Million EUR | 3.93% |
| 2020 | 562.94 Million EUR | 597.59% |
| 2019 | 80.69 Million EUR | 38.89% |
| 2018 | 58.1 Million EUR | -6.41% |
| 2017 | 62.07 Million EUR | 138.28% |
| 2016 | 26.05 Million EUR | -11.8% |
| 2015 | 29.54 Million EUR | -9.52% |
| 2014 | 32.64 Million EUR | -76.2% |
| 2013 | 137.2 Million EUR | 285.02% |
| 2012 | 35.63 Million EUR | -65.72% |
| 2011 | 103.94 Million EUR | 12.82% |
| 2010 | 92.13 Million EUR | -11.47% |
| 2009 | 104.07 Million EUR | -20.44% |
| 2008 | 130.81 Million EUR | 2565.42% |
| 2007 | 4.9 Million EUR | -82.77% |
| 2006 | 28.49 Million EUR | -33.42% |
| 2005 | 42.79 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 2.68 Billion EUR | 0.01% |
| 2024 Q1 | 2.98 Billion EUR | -14.96% |
| 2024 Q2 | 2.68 Billion EUR | -10.09% |
| 2023 Q1 | 1.11 Billion EUR | 0.04% |
| 2023 Q2 | 1.33 Billion EUR | 19.73% |
| 2023 Q3 | 3.75 Billion EUR | 182.36% |
| 2023 Q4 | 3.5 Billion EUR | -6.65% |
| 2023 FY | 3.5 Billion EUR | 215.71% |
| 2022 Q1 | 587.1 Million EUR | 0.35% |
| 2022 FY | 1.11 Billion EUR | 90.01% |
| 2022 Q2 | 586 Million EUR | -0.19% |
| 2022 Q3 | 1.09 Billion EUR | 86.33% |
| 2022 Q4 | 1.11 Billion EUR | 1.81% |
| 2021 Q3 | 579.3 Million EUR | 1.54% |
| 2021 Q4 | 585.07 Million EUR | 1.0% |
| 2021 FY | 585.07 Million EUR | 3.93% |
| 2021 Q1 | 568.9 Million EUR | 1.06% |
| 2021 Q2 | 570.5 Million EUR | 0.28% |
| 2020 Q2 | 299 Million EUR | 270.05% |
| 2020 Q1 | 80.8 Million EUR | 0.13% |
| 2020 FY | 562.94 Million EUR | 597.59% |
| 2020 Q4 | 562.94 Million EUR | 86.71% |
| 2020 Q3 | 301.5 Million EUR | 0.84% |
| 2019 Q4 | 80.69 Million EUR | -1.83% |
| 2019 FY | 80.69 Million EUR | 38.89% |
| 2019 Q2 | 81.3 Million EUR | 1.25% |
| 2019 Q3 | 82.2 Million EUR | 1.11% |
| 2019 Q1 | 80.3 Million EUR | 38.21% |
| 2018 Q3 | 58.9 Million EUR | -1.67% |
| 2018 Q1 | 61.2 Million EUR | -1.42% |
| 2018 Q4 | 58.1 Million EUR | -1.36% |
| 2018 FY | 58.1 Million EUR | -6.41% |
| 2018 Q2 | 59.9 Million EUR | -2.12% |
| 2017 Q4 | 62.07 Million EUR | -2.24% |
| 2017 FY | 62.07 Million EUR | 138.28% |
| 2017 Q1 | 24.8 Million EUR | -4.81% |
| 2017 Q2 | 24 Million EUR | -3.23% |
| 2017 Q3 | 63.5 Million EUR | 164.58% |
| 2016 FY | 26.05 Million EUR | -11.8% |
| 2016 Q3 | 27.2 Million EUR | -3.89% |
| 2016 Q2 | 28.3 Million EUR | -3.08% |
| 2016 Q1 | 29.2 Million EUR | -1.15% |
| 2016 Q4 | 26.05 Million EUR | -4.22% |
| 2015 Q4 | 29.53 Million EUR | -2.51% |
| 2015 Q3 | 30.3 Million EUR | -2.88% |
| 2015 Q2 | 31.2 Million EUR | -1.89% |
| 2015 Q1 | 31.8 Million EUR | -2.6% |
| 2015 FY | 29.54 Million EUR | -9.52% |
| 2014 FY | 32.64 Million EUR | -76.2% |
| 2014 Q4 | 32.65 Million EUR | -74.49% |
| 2014 Q3 | 128 Million EUR | -7.71% |
| 2014 Q2 | 138.7 Million EUR | -7.16% |
| 2014 Q1 | 149.4 Million EUR | 6.88% |
| 2013 FY | 137.2 Million EUR | 285.02% |
| 2013 Q4 | 139.78 Million EUR | 38.53% |
| 2013 Q2 | 30.8 Million EUR | 0.0% |
| 2013 Q3 | 100.9 Million EUR | 227.6% |
| 2012 FY | 35.63 Million EUR | -65.72% |
| 2012 Q2 | 139.3 Million EUR | 0.0% |
| 2011 Q2 | 110.6 Million EUR | 0.0% |
| 2011 FY | 103.94 Million EUR | 12.82% |
| 2010 Q2 | 112.6 Million EUR | 0.0% |
| 2010 FY | 92.13 Million EUR | -11.47% |
| 2009 FY | 104.07 Million EUR | -20.44% |
| 2009 Q4 | 104.07 Million EUR | 0.0% |
| 2008 FY | 130.81 Million EUR | 2565.42% |
| 2007 FY | 4.9 Million EUR | -82.77% |
| 2006 FY | 28.49 Million EUR | -33.42% |
| 2005 FY | 42.79 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | - USD | -Infinity% |
| Ansell Limited | 705.27 Million USD | -397.634% |
| Ansell Limited | 706.6 Million USD | -396.703% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 22.41 Million USD | -15560.22% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | - USD | -Infinity% |
| Psykey, Inc. | 625 Thousand USD | -561452.0% |
| ConvaTec Group Plc | 1.22 Billion USD | -186.467% |
| ConvaTec Group Plc | 1.22 Billion USD | -186.062% |
| Encision Inc. | 67.33 Thousand USD | -5212119.318% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 382.83 Thousand USD | -916660.919% |
| LifePoint, Inc. | 151.73 Thousand USD | -2312961.015% |
| Medite Cancer Diagnostics, Inc. | 4.91 Million USD | -71322.466% |
| Paradigm Medical Industries, Inc. | 615 Thousand USD | -570582.927% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | - USD | -Infinity% |
| Reflect Scientific, Inc. | 179.96 Thousand USD | -1950134.215% |
| SmileDirectClub, Inc. | 849.37 Million USD | -313.208% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 210.77 Million USD | -1565.102% |
| SheerVision, Inc. | - USD | -Infinity% |
| United Health Products, Inc. | 48.48 Thousand USD | -7238036.485% |
| Vasamed, Inc. | 18.95 Thousand USD | -18520744.327% |
| Wearable Health Solutions, Inc. | 18.46 Thousand USD | -19004123.522% |
| Yubo International Biotech Limited | 390.44 Thousand USD | -898797.412% |